Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SEAGEN INC. |
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 213.17 USD | +0.44% | -0.21% | +65.94% | |
| Sep. 22 | Hawkish Remarks by Fed Officials Weigh on Equity Markets | MT |
| Sep. 22 | Hawkish Remarks by Fed Officials Weigh on Equity Markets | MT |
Financials (USD)
| Sales 2023 * | 2,407 M | Sales 2024 * | 3,184 M | Capitalization | 39 837 M |
|---|---|---|---|---|---|
| Net income 2023 * | -650 M | Net income 2024 * | -266 M | EV / Sales 2023 * | 15,9x |
| Net cash position 2023 * | 1,498 M | Net cash position 2024 * | 1,885 M | EV / Sales 2024 * | 11,9x |
| P/E ratio 2023 * | -62,6x | P/E ratio 2024 * | -152x | Employees | - |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.15% | ||
| 1 week | +2.83% | ||
| Current month | +2.99% | ||
| 1 month | +2.90% | ||
| 3 months | +9.48% | ||
| 6 months | +4.54% | ||
| Current year | +65.15% |
1 week
212.15
217.08
1 month
203.61217.08
Current year
126.47217.08
1 year
116.08217.08
3 years
105.43217.08
5 years
50.71217.08
10 years
26.02217.08
| Managers | Title | Age | Since |
|---|---|---|---|
David Epstein
CEO | Chief Executive Officer | 61 | Nov. 08 |
Roger Dansey
CTO | Chief Tech/Sci/R&D Officer | 67 | 2018 |
Todd Simpson
DFI | Director of Finance/CFO | 62 | 2005 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Felix Baker
CHM | Chairman | 54 | 2022 |
David Epstein
BRD | Director/Board Member | 61 | Nov. 08 |
Nancy Simonian
BRD | Director/Board Member | 62 | 2012 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.99% | 189 M$ | -5.94% | - | |
| 2.68% | 2 M$ | -0.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-09-29 | 213.27 | +0.49% | 580 610 |
| 23-09-28 | 212.24 | -0.15% | 1,299,094 |
| 23-09-27 | 212.55 | -1.67% | 3,383,466 |
| 23-09-26 | 216.16 | +0.30% | 2,974,834 |
| 23-09-25 | 215.52 | +0.85% | 1,876,335 |
Delayed Quote Nasdaq, September 28, 2023 at 04:00 pm EDT
More quotes
Seagen Inc. specializes in the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. Net sales break down by source of income as follows:
- product sales (88%);
- royalties (9.6%);
- licenses and collaboration agreements (2.4%).
Calendar
2023-10-25
- Q3 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
212.24USD
Average target price
225.41USD
Spread / Average Target
+6.21%
EPS Revisions
| 1st Jan change | Capi. (M$) | |
|---|---|---|
| +65.15% | 39 837 M $ | |
| -44.18% | 38 162 M $ | |
| -3.51% | 36 203 M $ | |
| -6.84% | 34 219 M $ | |
| -26.77% | 21 754 M $ | |
| +27.20% | 20 298 M $ | |
| -13.27% | 14 663 M $ | |
| -17.93% | 10 763 M $ | |
| -18.72% | 10 608 M $ | |
| -10.37% | 10 014 M $ |
